Corteria Pharmaceuticals is a spin-out company from Sanofi. The company is focused on the development of novel therapies for heart failure subpopulations: a first-in-class CRF2 peptide agonist for outpatient worsening heart failure (OWHF) and a first-in-class vasopressin neutralizing antibody for the treatment of acute heart failure with hyponatremia (AHF).
- CEO i Cofundador: Philip Janiak
- CSO i Cofundadora: Marie-Laure Ozoux
- Ubicació: París
- Pàgina web: corteriapharma.com